Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment.

IF 5.7 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Current Atherosclerosis Reports Pub Date : 2024-04-01 Epub Date: 2024-02-05 DOI:10.1007/s11883-024-01192-9

Anders Berg Wulff, Børge G Nordestgaard, Anne Langsted

{"title":"Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment.","authors":"Anders Berg Wulff, Børge G Nordestgaard, Anne Langsted","doi":"10.1007/s11883-024-01192-9","DOIUrl":null,"url":null,"abstract":"Purpose of review: Lipoprotein(a) is an important causal risk factor for cardiovascular disease but currently no available medication effectively reduces lipoprotein(a). This review discusses recent findings regarding lipoprotein(a) as a causal risk factor and therapeutic target in cardiovascular disease, it reviews current clinical recommendations, and summarizes new lipoprotein(a) lowering drugs.Recent findings: Epidemiological and genetic studies have established lipoprotein(a) as a causal risk factor for cardiovascular disease and mortality. Guidelines worldwide now recommend lipoprotein(a) to be measured once in a lifetime, to offer patients with high lipoprotein(a) lifestyle advise and initiate other cardiovascular medications. Clinical trials including antisense oligonucleotides, small interfering RNAs, and an oral lipoprotein(a) inhibitor have shown great effect on lowering lipoprotein(a) with reductions up to 106%, without any major adverse effects. Recent clinical phase 1 and 2 trials show encouraging results and ongoing phase 3 trials will hopefully result in the introduction of specific lipoprotein(a) lowering drugs to lower the risk of cardiovascular disease.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":null,"pages":null},"PeriodicalIF":5.7000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Atherosclerosis Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11883-024-01192-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Lipoprotein(a) is an important causal risk factor for cardiovascular disease but currently no available medication effectively reduces lipoprotein(a). This review discusses recent findings regarding lipoprotein(a) as a causal risk factor and therapeutic target in cardiovascular disease, it reviews current clinical recommendations, and summarizes new lipoprotein(a) lowering drugs.

Recent findings: Epidemiological and genetic studies have established lipoprotein(a) as a causal risk factor for cardiovascular disease and mortality. Guidelines worldwide now recommend lipoprotein(a) to be measured once in a lifetime, to offer patients with high lipoprotein(a) lifestyle advise and initiate other cardiovascular medications. Clinical trials including antisense oligonucleotides, small interfering RNAs, and an oral lipoprotein(a) inhibitor have shown great effect on lowering lipoprotein(a) with reductions up to 106%, without any major adverse effects. Recent clinical phase 1 and 2 trials show encouraging results and ongoing phase 3 trials will hopefully result in the introduction of specific lipoprotein(a) lowering drugs to lower the risk of cardiovascular disease.

Abstract Image

查看原文本刊更多论文

脂蛋白（a）新疗法：心血管风险评估和治疗的最新进展》。

综述目的：脂蛋白（a）是心血管疾病的重要致病危险因素，但目前尚无有效降低脂蛋白（a）的药物。本综述讨论了有关脂蛋白（a）作为心血管疾病的致病危险因素和治疗靶点的最新研究结果，回顾了当前的临床建议，并总结了降低脂蛋白（a）的新药：流行病学和遗传学研究已证实，脂蛋白（a）是心血管疾病和死亡率的致病风险因素。目前，全世界的指南都建议终身测量一次脂蛋白（a），为高脂蛋白（a）患者提供生活方式建议，并开始使用其他心血管药物。包括反义寡核苷酸、小干扰 RNA 和口服脂蛋白（a）抑制剂在内的临床试验显示，降低脂蛋白（a）的效果非常显著，降幅高达 106%，且无任何重大不良反应。最近的 1 期和 2 期临床试验结果令人鼓舞，正在进行的 3 期试验将有望推出特定的降脂蛋白（a）药物，以降低心血管疾病的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Atherosclerosis Reports 医学-

CiteScore

9.00

自引率

3.40%

发文量

审稿时长

6-12 weeks

期刊介绍： The aim of this journal is to systematically provide expert views on current basic science and clinical advances in the field of atherosclerosis and highlight the most important developments likely to transform the field of cardiovascular prevention, diagnosis, and treatment. We accomplish this aim by appointing major authorities to serve as Section Editors who select leading experts from around the world to provide definitive reviews on key topics and papers published in the past year. We also provide supplementary reviews and commentaries from well-known figures in the field. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.